Expanding immune system stimulation to revolutionize vaccines...
Stimulating the body’s immune system remains one of the most promising approaches to addressing the unmet needs of cancers, HIV, hepatitis C virus, and other chronic infectious diseases. Our vaccine technology platform is progressively showing its potential to establish a new paradigm to prevent and treat these life-altering diseases. Our growing pipeline of vaccine candidates based on this technology has now advanced to preclinical studies. These vaccines could potentially protect millions of people from sickness or death due to disease.
Current vaccine strategies based on inactivated or weakened viruses have been tremendously successful in reducing significant disease burden associated with the major killers of the 19th and 20th centuries. Unfortunately, their long development times, large development costs, and relative inability to react to rapidly changing strains means these approaches are not suitable for hard to treat infectious diseases of the 21st century. In the area of cancer, immune tolerance - the inability of our immune system to distinguish cancerous cells from normal cells - is a major challenge and new approaches are needed to help the immune system to recognize diseased cells.
The goal of VLPbio to overcome these limitations can only be achieved with cutting-edge thinking about immune stimulation and new methods of vaccine design, formulation, and delivery. Our proprietary Vaccine Technology (Q-VLP) is the cumulative result of decades of research by world leaders in this important, advancing field of medical science. The growing list of partners, collaborators and funding agencies that have chosen to embrace and support VLPbio and our technology is a testament to the potential of our promising vaccine platform. We are proud and appreciative of these relationships and very pleased with the results we have achieved to date.
At VLPbio, we are playing an integral role in defining the future of medicine. We invite you to join us on our journey: as an investor, a participant in our clinical studies, a partner, or just an interested observer.